 |
 Video: What is a Stock Split?
|
|
|
| Atreca is a clinical-stage biopharmaceutical company utilizing its platform primarily to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101. According to our Atreca stock split history records, Atreca has had 0 splits. | |
|
Atreca (BCEL) has 0 splits in our Atreca stock split history database.
Looking at the Atreca stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Atreca shares, starting with a $10,000 purchase of BCEL, presented on a split-history-adjusted basis factoring in the complete Atreca stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/21/2019 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$17.07 |
|
| End price/share: |
$0.10 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.44% |
|
| Average Annual Total Return: |
-65.50% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$56.22 |
|
| Years: |
4.87 |
|
|
|
|
|
